Reta Semaglutide: Clearing Up a Common Confusion

The biggest misconception: retatrutide is not a form of semaglutide

The confusion is understandable. Retatrutide ends in "-glutide", which is the suffix shared by several GLP-1 medicines including semaglutide, liraglutide and others. That suffix signals a class of peptide-based drugs, not a family descended from semaglutide specifically. Retatrutide is a triple agonist, acting on GIP, GLP-1 and glucagon receptors simultaneously. Semaglutide acts only on GLP-1 receptors. These are fundamentally different molecular structures developed by different pharmaceutical companies through entirely separate research programmes.

As of mid-2026, retatrutide has no marketing authorisation in the UK, the EU or the US for any indication. Phase 2 trial data published in the New England Journal of Medicine showed promising weight-loss signals, but phase 3 results are still maturing and regulatory submissions have not been completed. Describing it as "the next semaglutide" is speculation dressed up as fact. Anyone offering retatrutide through a UK online pharmacy or social-media channel right now is operating outside the licensed supply chain, which is a serious safety concern, the MHRA has warned repeatedly about counterfeit and unlicensed weight-loss medicines circulating online.

Semaglutide, by contrast, has a well-established regulatory record in the UK. It was first licensed here as Ozempic for type 2 diabetes, then as Wegovy at the higher 2.4 mg weekly dose for weight management, and most recently as an oral tablet approved by the MHRA in June 2026. Three separate authorisations; each reviewed on its own evidence.

What semaglutide is licensed to do in the UK right now

The Wegovy injection is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, pre-diabetes or obstructive sleep apnoea. Treatment starts at 0.25 mg weekly and is titrated by a prescriber, typically over several months, up to the 2.4 mg maintenance dose. The MHRA also approved a 7.2 mg single-dose pen on 14 April 2026 for adults with a BMI of 30 or above, extending the maintenance ceiling further.

Evidence from the STEP 1 trial (a 68-week study published in the New England Journal of Medicine) showed an average body-weight reduction of around 15% with the 2.4 mg weekly injection alongside lifestyle changes. That is the figure regulators relied on. You may read higher averages quoted elsewhere, but STEP 1 at 2.4 mg is the UK-licensed evidence base.

The oral Wegovy tablet, approved on 11 June 2026, targets the same patient group and reaches a 25 mg daily maintenance dose after a titration period. Trial data from the OASIS 4 study showed an average weight loss of around 13.6% over 64 weeks regardless of adherence, rising to roughly 17% among participants who stayed fully consistent with treatment. Room-temperature storage and no injections make it a genuinely different proposition for some people, though clinical suitability is always assessed individually. If you want to explore current semaglutide treatment options in more detail, that page covers both the injection and the tablet.

Where retatrutide fits, and what to do if you read about it

Retatrutide is legitimately interesting science. Its triple-agonist profile produced weight-loss figures in phase 2 trials that attracted significant attention, and several research groups and patient communities have followed its progress closely. If you have read about it and are wondering whether switching from semaglutide to retatrutide might be an option, the short answer is that there is nothing to switch to yet in the UK, legally or clinically. Our page on moving from semaglutide to retatrutide covers the research landscape and what to watch for as trials progress.

What matters in the meantime is that any medicine you take for weight management through a UK pharmacy must hold a valid MHRA marketing authorisation, be dispensed against a prescription written by a registered prescriber, and arrive from a pharmacy you can verify on the GPhC register. Those three things protect you from counterfeit products and from treatments that simply have not been tested enough to know their safety profile at scale.

If you are currently on Wegovy and wondering about what comes next, the right conversation is with your prescriber, not a forum. Dose, timing and any switch decisions belong in a clinical assessment. You can also review a summary of weight-loss treatment options on our site to understand what is currently available through a legal, regulated route.

The cost question people usually ask next

Once readers understand that retatrutide is not available, the next question tends to be whether semaglutide is worth the private cost right now. The honest answer is that the decision is personal and clinical, not purely financial. Wegovy's private price varies by dose and provider. If you are curious about what a full private prescription genuinely covers, our Wegovy prices page sets out the context, including what headline figures often leave out. One point worth knowing before a payday purchase or a Monday-morning order: a legitimate price always includes the clinical assessment, prescription and dispensing, any quote that excludes those is not a complete picture.

The semaglutide mix ratio page is another resource that comes up for people who have been offered compounded semaglutide, which is a separate and important topic in itself. Compounded versions carry different regulatory status from licensed products and should not be conflated with Wegovy. If you would like a broader grounding in how the medicine itself works, our guide to semaglutide is a useful place to start before discussing your options with a prescriber.

If you have questions about your own suitability for licensed semaglutide treatment, a free consultation with one of our prescribers is the right starting point. Check your eligibility at our treatment page.